NASDAQ:REPL

Replimune Group - REPL Stock Forecast, Price & News

$20.33

-0.14 (-0.68%)

(As of 12/1/2022 02:00 PM ET)

Add

Compare

Today's Range: $20.17
▼
$20.77
50-Day Range: $15.78
▼
$21.00
52-Week Range: $13.05
▼
$30.89

Volume: 1,735 shs
Average Volume: 279,429 shs
Market Capitalization: $1.01 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $42.00

Replimune Group MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 102.8% Upside
$42.00 Price Target
Short Interest: Healthy
5.66% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.28
Upright™ Environmental Score
News Sentiment: 0.93
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($3.02) to ($3.43) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

263rd out of 1,047 stocks

Biological Products, Except Diagnostic Industry

41st out of 173 stocks

3.5

Analyst's Opinion

Consensus Rating
Replimune Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $42.00, Replimune Group has a forecasted upside of 102.8% from its current price of $20.71.
Amount of Analyst Coverage
Replimune Group has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
5.66% of the float of Replimune Group has been sold short.
Short Interest Ratio / Days to Cover
Replimune Group has a short interest ratio ("days to cover") of 6.2.
Change versus previous month
Short interest in Replimune Group has recently decreased by 9.95%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Replimune Group does not currently pay a dividend.
Dividend Growth
Replimune Group does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Replimune Group has received a 69.41% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" product. See details.
Environmental Sustainability
The Environmental Impact score for Replimune Group is -1.28.

3.3

News and Social Media Coverage

News Sentiment
Replimune Group has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Replimune Group this week, compared to 1 article on an average week.
MarketBeat Follows
1 people have added Replimune Group to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Replimune Group insiders have not sold or bought any company stock.
Percentage Held by Insiders
23.80% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
80.93% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Replimune Group are expected to decrease in the coming year, from ($3.02) to ($3.43) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Replimune Group is -7.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Replimune Group is -7.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Replimune Group has a P/B Ratio of 2.68. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Replimune Group (NASDAQ:REPL) Stock

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Stock News Headlines

November 26, 2022 | americanbankingnews.com

Replimune Group, Inc. (NASDAQ:REPL) Receives $42.00 Average Target Price from Analysts

November 23, 2022 | finance.yahoo.com

Replimune to Present at the Piper Sandler 34th Annual Healthcare Conference

November 22, 2022 | finance.yahoo.com

Replimune to Host Virtual Investor Event on December 7, 2022

November 3, 2022 | finanznachrichten.de

Replimune Group Inc: Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update

October 15, 2022 | finance.yahoo.com

Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts

October 14, 2022 | markets.businessinsider.com

Expert Ratings for Replimune Group

August 24, 2022 | finance.yahoo.com

Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks

August 12, 2022 | seekingalpha.com

Replimune: Recent Developments Strengthen Bull Thesis

August 6, 2022 | finance.yahoo.com

Is Replimune Group (NASDAQ:REPL) Using Too Much Debt?

July 17, 2022 | uk.finance.yahoo.com

Replimune Group, Inc. (REPL)

June 3, 2022 | finance.yahoo.com

Replimune Announces the Departure of Jason Rhodes from its Board of Directors

June 2, 2022 | finance.yahoo.com

Replimune to Present at the Jefferies Healthcare Conference

May 30, 2022 | finance.yahoo.com

Is There An Opportunity With Replimune Group, Inc.'s (NASDAQ:REPL) 38% Undervaluation?

May 26, 2022 | finance.yahoo.com

Replimune To Present at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 24, 2022 | markets.businessinsider.com

Analyst Ratings for Replimune Group

May 19, 2022 | finance.yahoo.com

Replimune Reports Fiscal Fourth Quarter and Year-Ended 2022 Financial Results and Provides Corporate Update

April 14, 2022 | finance.yahoo.com

We Think Replimune Group (NASDAQ:REPL) Can Afford To Drive Business Growth

April 8, 2022 | marketwatch.com

Novavax Inc. stock outperforms market on strong trading day

April 4, 2022 | benzinga.com

JP Morgan Maintains Overweight on Replimune Group, Lowers Price Target to $39

March 30, 2022 | finance.yahoo.com

Replimune Provides New Clinical Data, Broad Program Update and Future Development Strategy for its Tumor-Directed Oncolytic Immunotherapies

March 21, 2022 | finance.yahoo.com

Replimune to Host Virtual Investor Event on March 30, 2022

February 11, 2022 | finance.yahoo.com

Replimune to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 3, 2022 | benzinga.com

Replimune Group: Q3 Earnings Insights

February 1, 2022 | nasdaq.com

Commit To Purchase Replimune Group At $12.50, Earn 11% Annualized Using Options

January 31, 2022 | finance.yahoo.com

Replimune Announces the Departure of Dr. Otello Stampacchia from its Board of Directors

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive REPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter.

REPL Company Calendar

Last Earnings: 11/04/2021
Today: 12/01/2022
Next Earnings (Estimated): 2/02/2023
Fiscal Year End: 3/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:REPL
CUSIP: N/A
CIK: 1737953
Web: www.replimune.com
Phone: (781) 222-9600
Fax: N/A
Employees: 152
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $42.00
High Stock Price Forecast: $52.00
Low Stock Price Forecast: $30.00
Forecasted Upside/Downside: +106.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.74)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-118,040,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -35.72%
Return on Assets: -31.86%

Debt

Debt-to-Equity Ratio: 0.06
Current Ratio: 16.12
Quick Ratio: 16.12

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.72 per share
Price / Book: 2.63

Miscellaneous

Outstanding Shares: 49,740,000
Free Float: 37,901,000
Market Cap: $1.01 billion
Optionable: Not Optionable
Beta: 1.86

Key Executives

Mr. Philip Astley-Sparke FSA (Age 51)
CEO & Director
Comp: $880.5k

Dr. Robert Coffin Ph.D. (Age 57)
Founder, Pres, Chief R&D Officer and Director
Comp: $785.89k

Ms. Tanya N. Lewis M.S. (Age 51)
Chief Devel. Operations Officer
Comp: $4.7k

Mr. Sushil Patel Ph.D. (Age 51)
Chief Commercial Officer
Comp: $594.58k

Ms. Jean M. Franchi (Age 56)
Principal Accounting Officer, CFO, Treasurer, Sec. & Compliance Officer

Dr. Colin A. Love Ph.D. (Age 64)
Chief Operating Officer

Dr. Pamela Esposito Ph.D. (Age 47)
Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

REPL Stock - Frequently Asked Questions

Should I buy or sell Replimune Group stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" REPL shares.
View REPL analyst ratings or view top-rated stocks.
What is Replimune Group's stock price forecast for 2023?: 6 Wall Street analysts have issued 12-month price objectives for Replimune Group's shares. Their REPL share price forecasts range from $30.00 to $52.00. On average, they predict the company's stock price to reach $42.00 in the next year. This suggests a possible upside of 104.5% from the stock's current price.
View analysts price targets for REPL or view top-rated stocks among Wall Street analysts.
How have REPL shares performed in 2022?: Replimune Group's stock was trading at $27.10 on January 1st, 2022. Since then, REPL shares have decreased by 24.2% and is now trading at $20.54.
View the best growth stocks for 2022 here.
When is Replimune Group's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
View our REPL earnings forecast.
How were Replimune Group's earnings last quarter?: Replimune Group, Inc. (NASDAQ:REPL) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by $0.05.
What other stocks do shareholders of Replimune Group own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

When did Replimune Group IPO?: (REPL) raised $100 million in an initial public offering (IPO) on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.
What is Replimune Group's stock symbol?: Replimune Group trades on the NASDAQ under the ticker symbol "REPL."
Who are Replimune Group's major shareholders?: Replimune Group's stock is owned by a variety of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (8.39%), Atlas Venture Life Science Advisors LLC (6.25%), BlackRock Inc. (5.56%), Vanguard Group Inc. (3.72%), State Street Corp (2.92%) and Emerald Advisers LLC (2.31%). Insiders that own company stock include Colin Love, Fund Iv LP Omega, Jason P Rhodes, Jean M Franchi, Pamela Esposito, Philip Astley-Sparke and Robert Coffin.
View institutional ownership trends.
How do I buy shares of Replimune Group?: Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Replimune Group's stock price today?: One share of REPL stock can currently be purchased for approximately $20.54.
How much money does Replimune Group make?: Replimune Group (NASDAQ:REPL) has a market capitalization of $1.02 billion. The company earns $-118,040,000.00 in net income (profit) each year or ($2.74) on an earnings per share basis.
How many employees does Replimune Group have?: The company employs 152 workers across the globe.
How can I contact Replimune Group?: Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The official website for the company is www.replimune.com. The company can be reached via phone at (781) 222-9600 or via email at ir@replimune.com.

This page (NASDAQ:REPL) was last updated on 12/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial